RESUMO
Objective:To investigate the effect of miRNA-126 on proliferation, apoptosis and migration of thyroid cancer SW579 cells, and further to explore its mechanism.Methods:Thyroid cancer SW579 cells were cultured in vitro, and the expression of miRNA-126 in normal thyroid Nthy-ori3-1 cells and SW579 cells was detected by qPCR. The cells were divided into blank control group (without any treatment) , experimental group (transfected with miRNA-126 expression plasmid) and negative control group (transfected with empty plasmid vector) . SW579 cells with overexpression of miRNA-126 were constructed by transfection of plasmids. CCK-8 test was used to detect cell proliferation; Transwell cell test was used to detect cell migration and invasion; Flow cytometry was employed to detect apoptosis and changes in reactive oxygen levels; Western blot was used to detect Notch-1/Akt pathway related protein expression.Results:The expression level of miRNA-126 in SW579 cells was 0.25±0.07, and the difference was statistically significant compared with that in Nthy-ori3-1 cells (P<0.001) . The cell survival rates of blank control group, experimental group and negative control group were (105.70 ± 7.61) , (98.60 ± 5.42) and (62.70 ± 3.82) ; The apoptosis rates were (9.14 ± 0.83) , (12.28 ± 1.34) and (36.39 ± 3.21) (all P < 0.05) ; The cell migration rates were (34.51 ± 2.45) , (33.29 ± 3.17) and (11.22 ± 1.23) (all P < 0.05) ; The levels of ROS were (1.02 ± 0.07) , (1.08 ± 0.11) and (6.54 ± 0.74) (all P < 0.05) .Conclusion:Overexpression of miR-NA-126 can inhibit Notch-1/Akt pathway by up-regulating intracellular reactive oxygen species, inhibit the proliferation and migration of SW579 cells, and induce apoptosis in SW579 cells, which provides a certain basis for the study of miRNA-126 in thyroid cancer.
RESUMO
Objective Controversy exists over the effects of postoperative chemoradiotherapy or chemotherapy in the treatment of rectal cancer. This study aims to evaluate the clinical effect of chemoradiotherapy or chemotherapy following radical surgery for stage Ⅱ-Ⅲrectal cancer. Methods We retrospectively analyzed the clinical data of 125 cases of stageⅡ-Ⅲrectal cancer receiving chemo-radiotherapy ( n=69) or chemotherapy ( n=56) after radical surgery. The patients in the chemoradiotherapy group were treated by 3-di-mensional conformal or intensity-modulated radiotherapy at a total irradiation dose of 45-50 Gy/25-28 times and concurrently by XE-LOX/FOLFOX chemotherapy for 4-6 cycles. Those in the chemotherapy group underwent XELOX/FOLFOX chemotherapy only, at the same dose and for the same length of time as the former. Results The therapeutic effect on stageⅡ-Ⅲrectal cancer was not correla-ted with the gender, family history, smoking history, drinking history, high-fat intake, sedentariness, obesity or constipation of the pa-tient, nor with the TNM stage, pathological grade or differentiation degree of the disease. The 1-, 2-, and 3-year survival rates were sig-nificantly higher in the chemoradiotherapy group (86. 9%, 76. 8%, and 57. 9%) than in the chemotherapy group (71. 4%, 58. 9%, and 39. 3%) (P0. 05). Conclusion For stageⅡ-Ⅲrectal cancer, postoperative chemoradio-therapy is a safe and effective option , which can evidently reduce local recurrence and improve 3-year survival of the patient.